Marvel Biosciences Corp. (TSXV:MRVL)
Canada · Delayed Price · Currency is CAD | Market Cap | 9.14M +75.1% |
| Revenue (ttm) | n/a |
| Net Income | -2.09M |
| EPS | -0.04 |
| Shares Out | 63.03M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 81,375 |
| Average Volume | 61,613 |
| Open | 0.1600 |
| Previous Close | 0.1500 |
| Day's Range | 0.1500 - 0.1600 |
| 52-Week Range | 0.0750 - 0.4000 |
| Beta | 0.62 |
| RSI | 44.92 |
| Earnings Date | Jun 17, 2026 |
About Marvel Biosciences
Marvel Biosciences Corp., a biotechnology company, develops synthetic chemical derivatives of the original approved drug for the new disease indication in Canada. The company’s lead compound MB-204, a novel fluorinated derivative of istradefylline, an adenosine A2a receptor antagonist to treat alzheimer’s disease and autism spectrum disorder, as well as depression and anxiety. It provides non-hallucinogenic neuroplasticity program. The company is headquartered in Calgary, Canada. [Read more]
Financial Performance
Financial StatementsNews
Marvel Biosciences Announces Grant of Deferred Share Units
Calgary, Alberta--(Newsfile Corp. - May 20, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announces...
Marvel Biosciences to Participate and Present at the 2nd Neuroscience Innovation Partnering and Licensing Summit
Marvel Biosciences to participate in 2nd Neuroscience Innovation Partnering & Licensing Summit, allowing Marvel to showcase its progress on global stage
Marvel Biosciences Announces Closing of Convertible Debenture Offering
Calgary, Alberta--(Newsfile Corp. - April 17, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) ("Marvel" or the "Company") announced today that it has completed the closing of the previously announced no...
Marvel Biosciences Identifies Liquid Formulations for Neurodevelopmental Disorders
CALGARY, Alberta, April 16, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Compa...
Marvel Biosciences Announces an Amendment to the Conversion Price for Marvel's Proposed Convertible Debenture Offering
Calgary, Alberta--(Newsfile Corp. - April 13, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) ("Marvel" or the "Company") Further to the Company's press release of April 8, 2026, announcing its intentio...
Marvel Biosciences Announces Proposed Convertible Debenture Offering
Calgary, Alberta--(Newsfile Corp. - April 8, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) ("Marvel" or the "Company") announced today its intention to complete a non-brokered private placement offeri...
Marvel Biosciences Secures Financial and Strategic Investment with 5 Horizon Ventures
Marvel announces financial and strategic backing from 5 Horizons Ventures to support its upcoming Phase 1 clinical trial of patented lead asset MB-204
Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204
Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204, lead asset discovery, a patented neuroactive adenosine A2A antagonist
Marvel Biosciences Receives Notice of Allowance for US Patent Application Covering Composition of Matter for Its Lead Therapeutic Candidate MB-204
Calgary, Alberta--(Newsfile Corp. - March 18, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or the "Co...
Marvel Biosciences Sponsors Scientific Meeting on Purines
Calgary, Alberta--(Newsfile Corp. - March 4, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or the "Com...
Marvel Biosciences Announces Grant of Deferred Share Units
Calgary, Alberta--(Newsfile Corp. - February 18, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), anno...
Marvel Biosciences Receives Japanese Patent Covering Composition of Matter for Its Lead Therapeutic Candidate MB-204
Calgary, Alberta--(Newsfile Corp. - February 3, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or the "...
Toronto Stock Exchange, Marvel Biosciences Corp., The View from the C-Suite
Toronto, Ontario--(Newsfile Corp. - December 22, 2025) - Rod Matheson, Chief Executive Officer, and Mark Williams, Chief Strategy Officer, from Marvel Biosciences Corp. (the "Company") (TSXV: MRVL), s...
Marvel Biosciences Announces Acceleration of Warrant Expiry Date
Calgary, Alberta--(Newsfile Corp. - October 3, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is ann...
Marvel Biosciences Granted Chinese Patent for Lead Therapeutic Candidate MB-204
Calgary, Alberta--(Newsfile Corp. - August 18, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or the "C...
Marvel Biosciences Announces Closing of Private Placement
Calgary, Alberta--(Newsfile Corp. - May 12, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announces...
Marvel Biosciences Announces Closing of Second Tranche of Private Placement
Calgary, Alberta--(Newsfile Corp. - May 2, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased...
Marvel Announces the Second of Two Final Data Sets from Rett Syndrome Study: MB-204 Significantly Outperforms Trofinetide Following Cessation of Drug Treatment
Calgary, Alberta--(Newsfile Corp. - April 30, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "M...
Marvel Biosciences to Give Oral Presentation at The Annual IRSF Rett Syndrome Scientific Meeting
Calgary, Alberta--(Newsfile Corp. - April 16, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (together "Marvel"), are pleased ...
Marvel Biosciences Selected to Present Alzheimer's Research at the 2025 Alzheimer's Association International Conference
Calgary, Alberta--(Newsfile Corp. - April 14, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or the "Co...
Marvel Biosciences Announces Private Placement
Calgary, Alberta--(Newsfile Corp. - March 28, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is plea...
Marvel to File for Orphan Drug Designation with The U.S. FDA for MB-204 as a Treatment for Rett Syndrome
Calgary, Alberta--(Newsfile Corp. - March 17, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "M...
Marvel Announces First of Two Final Data Sets from Rett Syndrome Study: MB-204 Significantly Outperforms Trofinetide
Calgary, Alberta--(Newsfile Corp. - March 13, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Ma...
Marvel Presenting at the 2025 Bloom Burton & Co. Conference
Calgary, Alberta--(Newsfile Corp. - March 11, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "M...
Marvel Biosciences Announces Private Placement for up to $2.5 Million
Calgary, Alberta--(Newsfile Corp. - January 7, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) ("Marvel" or the "Company") is pleased to announce that it intends to complete a non-brokere...